FY2024 Earnings Estimate for VIGL Issued By William Blair

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Investment analysts at William Blair issued their FY2024 earnings per share (EPS) estimates for Vigil Neuroscience in a note issued to investors on Tuesday, December 3rd. William Blair analyst S. Schram expects that the company will post earnings of ($2.00) per share for the year. William Blair has a "Outperform" rating on the stock. The consensus estimate for Vigil Neuroscience's current full-year earnings is ($2.07) per share. William Blair also issued estimates for Vigil Neuroscience's FY2025 earnings at ($2.30) EPS.

VIGL has been the subject of several other reports. Wedbush lifted their target price on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an "outperform" rating in a report on Friday, November 8th. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Vigil Neuroscience in a research report on Friday, November 8th. JMP Securities reissued a "market outperform" rating and issued a $22.00 target price on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Finally, Guggenheim decreased their price target on Vigil Neuroscience from $17.00 to $16.00 and set a "buy" rating for the company in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.60.

Vigil Neuroscience Stock Performance

Vigil Neuroscience stock traded up $0.02 during mid-day trading on Friday, reaching $2.33. The stock had a trading volume of 302,105 shares, compared to its average volume of 209,476. Vigil Neuroscience has a one year low of $2.08 and a one year high of $6.06. The company has a 50-day moving average price of $3.31 and a two-hundred day moving average price of $3.59.

Institutional Trading of Vigil Neuroscience

Large investors have recently modified their holdings of the company. Acadian Asset Management LLC bought a new position in Vigil Neuroscience in the second quarter worth approximately $26,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Vigil Neuroscience in the 2nd quarter worth $87,000. Renaissance Technologies LLC raised its holdings in Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company's stock worth $286,000 after purchasing an additional 11,536 shares during the period. Walleye Capital LLC lifted its position in Vigil Neuroscience by 334.4% during the third quarter. Walleye Capital LLC now owns 119,792 shares of the company's stock valued at $407,000 after purchasing an additional 92,217 shares in the last quarter. Finally, Verition Fund Management LLC bought a new stake in Vigil Neuroscience during the third quarter valued at about $442,000. Institutional investors own 83.64% of the company's stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.